News & Views
At Enveda, we are tackling the toughest challenges in drug discovery, finding and developing new compounds from the expanse of the natural world.
Subscribe to follow our progress.
Highlights
06/21/2023
Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code
The algorithm, MS2Mol, powers Enveda’s drug discovery platform which finds new medicines in nature with unprecedented speed
Read more
6/20/2023
MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature
In many ways, life is chemistry. Metabolism, DNA replication, cell division, all of life's essential processes are – at their most essential – a series of chemi
Read more05/08/2023
Enveda Selected to Present Latest Work in Natural Language Processing at ICLR 2023
Multi-scale Sinusoidal Embeddings Enable Learning on High Resolution Mass Spectrometry Data
Read more04/20/2023
Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million
New investor Kinnevik led the round with outsized participation from current investors. The company is advancing multiple candidates toward the clinic
Read more03/08/2023
Inspirational Women of Enveda
We asked eight of Enveda's inspirational women to tell us about their role and what they'd tell their younger self about it
Read more02/22/2023
GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra
The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed
Read more
02/15/2023
Enveda's matured platform drives toward three INDs in 2023
CEO Viswa Colluru believes Enveda has found the answer in a platform that combines metabolomics and ML to predict unknown chemistry at unprecedented accuracy
Read more12/21/2022
Enveda closes $68-million combined Series B equity and debt financing
Round included multiple new institutional investors and all its current major investors
Read more_logo.svg){kind=logo}
11/11/2022
TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data
The core problem in natural product drug discovery: finding needles in nature’s haystack.
Read moreNews
Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code
06/21/2023
The algorithm, MS2Mol, powers Enveda’s drug discovery platform which finds new medicines in nature with unprecedented speed
MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature
6/20/2023
In many ways, life is chemistry. Metabolism, DNA replication, cell division, all of life's essential processes are – at their most essential – a series of chemi
Enveda Selected to Present Latest Work in Natural Language Processing at ICLR 2023
05/08/2023
Multi-scale Sinusoidal Embeddings Enable Learning on High Resolution Mass Spectrometry Data
Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million
04/20/2023
New investor Kinnevik led the round with outsized participation from current investors. The company is advancing multiple candidates toward the clinic
Inspirational Women of Enveda
03/08/2023
We asked eight of Enveda's inspirational women to tell us about their role and what they'd tell their younger self about it
GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra
02/22/2023
The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed
Enveda's matured platform drives toward three INDs in 2023
02/15/2023
CEO Viswa Colluru believes Enveda has found the answer in a platform that combines metabolomics and ML to predict unknown chemistry at unprecedented accuracy
Searching for Medicine’s Answers in the Most Powerful Library on Earth
01/19/2022
“We started Enveda to build the first high-resolution chemical map of planet Earth and change where we look for new medicines."
'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023
12/21/2022
Enveda will enter the clinic next year with at least one of three main programs
Enveda closes $68-million combined Series B equity and debt financing
12/21/2022
Round included multiple new institutional investors and all its current major investors
TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data
11/11/2022
The core problem in natural product drug discovery: finding needles in nature’s haystack.
Natural Products in Protein Degradation: Past, Present, and Future
10/19/2022
Protein degradation, whether as a PROTAC (proteolysis targeting chimera) or a molecular glue, is an emerging new modality of therapeutic action...
Enveda Biosciences to Open Advanced Drug Discovery and Development Center in Boulder, Colo.; Lead Optimization Laboratory in Hyderabad, Telangana, India
04/07/2022
Enveda Biosciences to Open Advanced Drug Discovery and Development Center in Boulder, Colo.; Lead Optimization Laboratory in Hyderabad, Telangana, India...
Enveda Biosciences Adds Drug Development Leaders to Scale Efforts and Accelerate Progress
03/17/2022
New team members deepen Enveda’s global drug development expertise as its therapeutics pipeline expands and advances...
A Recursion veteran is mapping plant life to chart a course to new therapies — and investors like what they see
06/22/2021
One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving...
Lux Capital Leads $51 Million Financing in Biotech Startup Enveda - Company searches for compounds from nature to develop medications
06/22/2021
Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped...
Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital
06/22/2021
Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announc...
Exploiting the Therapeutic Potential of Plants
03/02/2021
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of...
Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database
12/16/2020
Enveda Bioscienes has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biologi...
Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics
12/16/2020
Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures...
Why we invested in Enveda
12/16/2020
In the Spring of 2018, one of our LPs based in Salt Lake City introduced me to a founder named Dan Wee from the vibrant bioscience community there...
Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation
03/02/2018
It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound...
Mass spectrometry searches using MASST
01/01/2020
Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query...
Global chemical effects of the microbiome include new bile-acid conjugations
02/26/2020
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes...
Celebrating the departure of an outstanding employee
04/02/2019
A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion...
Blog
MS2Mol: a transformer encoder-decoder model for exploring the dark chemical space of nature
This is a continuation of a series of blogs on teaching computers the language of chemistry
Inspirational Women of Enveda
We asked inspiring Enveda women to tell us about their roles and what they'd tell their younger self about that their journey
GRAFF-MS: a new scalable ML model for accurate prediction of small molecule mass spectra
The model uses graph neural networks to predict mass spectra and outperforms existing alternatives in both accuracy and speed
Natural Products as Drugs: Evolution as Master Medicinal Chemist
Where are the richest caches of “drug-like” molecules?
Machine Learning will Revolutionize Metabolomics
Metabolomics is a rapidly emerging field that seeks to measure the landscape of metabolites, or organic small molecules, in liv...
Fulfilling the Promise of Natural Products with Technology: Discovering the Next Generation of Small Molecules
In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four mole...
Drug Discovery Productivity at Enveda —Biotech Innovation with Big Pharma Efficiency
Once the initial project goals are defined, biologists build assays that can reproducibly evaluate compounds (agonists, antagon...
Artemisinins, Malaria, and The Quest to Systematize Collaboration between Nature and Scientists (Cures and Nobel Prizes)
Mother Nature is, by far, the most accomplished drug discovery researcher in the history of the world, in spite of the fact..
Subscribe To Follow Our Progress.
Quick links
Locations
